Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Acetyl tributyl citrate, best known as ATBC, has collected a long history since its early days in the chemical industry. Manufacturers started using it as a safe plasticizer in the mid-20th century, especially once communities and regulators grew tired of phthalate-based compounds linked to health risks. High-profile recalls, consumer demand for transparency, and the relentless push for safer materials drove the global shift toward non-phthalate alternatives. ATBC quickly found supporters in the pharmaceutical world. The British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP) ratified quality standards for this compound. Generations after its introduction, ATBC stands as a go-to for anyone seeking a consistent, reproducible, and human-friendly plasticizer.
Pharma-grade ATBC carries a stamp of purity that few other excipients can match. Producers design it specifically for applications demanding extreme consistency and safety—think pharmaceutical coatings, capsules, and controlled-release platforms. On the bench or in a factory, ATBC's clarity, absence of strong odor, and ability to flow without clumping make life easier. Regulatory authorities like the FDA and EMA emphasize low impurity thresholds and stability, so each bottle comes with a complete chain of custody and a Certificate of Analysis. Doctors, pharmacists, and patients benefit from this assurance, as there's less risk of unexpected reactions or contamination.
ATBC fits invisibly into many pharmaceutical recipes because of its physical and chemical traits. It's a clear, oily liquid at room temperature, and dissolves in organic solvents but resists breaking down in water. Its molecular weight hovers near 402.5 g/mol, and a boiling point above 300°C keeps it stable even under tough processing. Its low volatility, mild aroma, and flexibility over a wide temperature range let formulators dial in texture and elasticity in coatings or films. These properties drive its use in oral solid dosages, topical gels, and film coatings where consistent release matters. Chemists also appreciate its resistance to hydrolysis in neutral and slightly acidic environments—essential for medicines stored long-term in plastic containers.
Each drum or vial of pharma-grade ATBC matches a strict technical profile, tightly monitored by quality assurance teams. The purity threshold sits above 99.5%. Moisture content doesn’t exceed 0.2%, while acid value stays below 0.2 mg KOH/g. Heavy metals like lead and arsenic must fall well under internationally recognized safety thresholds; reputable suppliers run tests to show levels below 1 ppm. Detailed labeling lists batch number, manufacturing and expiry dates, storage conditions, and certifying standard (BP, EP, or USP)—helping trace issues if problems crop up further down the line. Tamper-evident seals and color codes confirm intact, authentic material for anyone in procurement or regulatory roles. An auditor or pharmacist, for example, can quickly pinpoint where any deviation took place just by referencing documentation.
Industry-scale production of ATBC relies on reacting citric acid—often sourced from corn starch—with n-butanol in the presence of acetic anhydride and an acid catalyst, then purifying the resulting ester. Teams separate byproducts through washing and distillation, removing color bodies and residual hydrocarbons. Each batch must meet tight tolerance levels for both chemical content and physical appearance. Manufacturing facilities swear by closed systems and inert gas overlays to stop air or water contamination. These steps demand regular validation; skipping even one check risks leftover solvent traces or higher impurity levels, which no regulatory agency accepts for injectable or oral medicine.
ATBC's structure makes it remarkably stable under most pharmaceutical storage conditions. Its three butyl ester branches shield the central citric acid skeleton, making it slow to hydrolyze. Under harsh alkaline or acidic stress, ATBC may slowly break down into tributyl citrate and other less reactive products, but at physiological pH, it holds together robustly. This trait sets ATBC apart from many other esters, which struggle with shelf-life or release unwanted byproducts. Though relatively inert, some research groups experiment with modified ATBC derivatives, tweaking the alkyl side chains to explore new solubility or release characteristics for next-generation drugs.
ATBC often appears under alternate labels in technical literature, such as acetyltri-n-butyl citrate, Citroflex A-4, ATEC, and Acetyltributylcitrat. Different suppliers adopt their in-house names and catalog identifiers, but chemical identifiers such as CAS 77-90-7 remain the clearest link between brands. International pharmacopoeias or regulatory submissions may list ATBC, ATEC, and similar aliases interchangeably, while product datasheets stick with the full chemical name to avoid ambiguity. For pharmacists or scientists scouring safety sheets and supply catalogs, this network of trade and chemical names can pose a documentation challenge—but with a little vigilance, cross-referencing avoids costly mix-ups.
ATBC earned its pharmaceutical-grade credentials through an impressive track record of biocompatibility. It lacks the hormone-disrupting properties of some earlier plasticizers, and repeated toxicity assessments show low acute and chronic effects in test animals. Regulatory agencies demand batch-release testing for not just purity and impurity content but also for residual solvents, heavy metals, and allergens. Workers filling capsules or coating tablets work under local exhaust ventilation and wear gloves or goggles, but daily exposure to ATBC poses little risk compared to more reactive reagents. Spills clean up easily with soap and water. To support patient safety, manufacturers review all supplier documentation and trace contamination risks back to individual raw material batches. In most real-world applications, the low volatility and lack of skin sensitization reports keep ATBC among the safest film-formers for oral and topical medications.
Pharma-grade ATBC finds its most visible application in film coatings for tablets and capsules, providing flexibility and compressibility where brittle alternatives break down. Extended-release tablets often rely on ATBC to slow water penetration and allow steady absorption over hours, improving symptom control for patients managing pain, hypertension, or mental health conditions. Injectable preparations sometimes use ATBC as a solvent or co-solvent due to its low toxicity profile and predictable performance under sterilization. It also shows up in oral suspensions, pediatric medicines, and some eye drops, where non-irritating and hypoallergenic excipients become non-negotiable. Beyond human medicine, veterinary pharmaceuticals and certain nutraceuticals rely on ATBC for the same reasons—reducing adverse events and meeting customer demands for “clean label” ingredients.
University labs and corporate formulation teams continually revisit ATBC’s limits and possible new applications. Controlled-release technology, for instance, benefits from studies mapping how ATBC influences water permeability and polymer relaxation in multi-layer coatings. Several groups exploit ATBC to stabilize sensitive biologics or probiotics, running shelf-life studies under high heat or humidity. Analytical research focuses on trace detection of ATBC and its degradation products to aid pharmacovigilance and environmental monitoring. The migration profile in packaging is another active area, especially where long-term drug integrity matters most. Each new regulatory submission brings requests for updated stability data, keeping technical teams busy refining production and analytical protocols.
Over the decades, toxicologists pushed ATBC through rigorous animal and clinical studies. Oral doses at levels far beyond pharmaceutical use show low systemic toxicity, minimal reproductive or developmental effects, and no convincing evidence of carcinogenicity or mutagenicity. Metabolic profiling reveals rapid breakdown and excretion, with minimal accumulation in tissues. Human volunteer studies—rare but valuable—have supported low irritation and allergenic risk. Authorities in Europe, the US, and Japan capped acceptable daily intake well above actual exposures, fueling the compound’s reputation as a workhorse for sensitive applications. Ongoing vigilance remains important; surveillance systems track reports of rare topical sensitivities or contact reactions. So far, these incidents never reached statistically significant levels to prompt warnings or restrictions at approved doses.
Looking ahead, ATBC’s relevance seems poised to grow. As regulators tighten controls on legacy phthalates and demand concrete evidence of excipient safety, more manufacturers look toward “old reliable” compounds with proven track records. The rise of targeted oral therapies, pediatric formulations, and patient-customized dosages puts pressure on excipient suppliers to deliver materials that won’t trigger allergic, endocrine, or genotoxic responses. Green chemistry advocates also target fossil-derived plasticizers for replacement, and bio-based sourcing of citric acid makes ATBC look even more attractive. Emerging drug delivery technologies, such as 3D-printed pills and smart coatings that respond to pH or temperature, open the door to even broader application. Formulators continue exploring subtle modification of ATBC’s molecular structure—tweaking hydrophobicity or melting range to unlock even more control over drug release. The steady hand of regulatory guidance and evolving patient needs will define ATBC’s place in pharmaceutical manufacturing for years to come.
Pharmaceutical companies count on special ingredients like ATBC—short for acetyl tributyl citrate—to help medicines do what they're supposed to do. ATBC serves as a plasticizer. That means it keeps things flexible, especially in products like capsules and tablets. When you swallow a pill, you probably don't think about how it stays intact before you take it, yet dissolves smoothly once inside you. ATBC keeps capsule shells from becoming brittle during storage, transport, and daily handling.
Purity levels matter a lot in medicine. Terms like BP, EP, and USP refer to pharmacopeia standards from Britain, Europe, and the United States. Each set of rules tells labs how clean a chemical needs to be before it touches a medicine. Medicine makers go for these grades because impurities can harm patients, weaken drugs, or throw off how long a product stays safe on the shelf. In the past, I’ve worked with quality assurance teams that have spent endless hours chasing down tiny contaminants in batches—all in pursuit of these strict standards. ATBC at pharma grade levels cuts these worries down and keeps labs focused where it counts.
There’s a lot of talk right now about what goes in and on pharmaceuticals. People have become careful about what enters their bodies, even in tiny amounts. ATBC carries a safer track record than some older phthalate plasticizers, which caused problems years ago over hormone disruption. Regulators responded by tightening limits and frequently checking ingredient lists. ATBC’s reputation as a safer plasticizer comes from several safety studies. Labs have reviewed its toxicology and found low risk for the doses and uses common in pharmaceuticals. That trust doesn’t come easy; it builds through years of researchers testing absorption, metabolism, and side effects.
Every time a fresh batch of raw materials like ATBC arrives at a drug plant, someone in a lab coat tests it. This chain of checks—identity, purity, and safety—builds up trust from manufacturing to the patient opening a blister pack. Last year, a recall made headlines because one supplier cut corners with their plasticizer, leading to product withdrawals and heavy financial losses. ATBC that lives up to BP, EP, or USP standards gets its paperwork checked, its purity measured, and its source traced. Real transparency is what separates a pharma-grade supply chain from one built only for industrial products.
Nothing in pharmaceutical production happens by accident. Decisions about plasticizers like ATBC connect directly to patient safety, drug reliability, and even how much waste gets tossed out during manufacturing. Pills that fall apart too soon or don’t dissolve right can cost lives or spark lawsuits. Choosing the correct ATBC grade stands as part of the careful web that keeps medicines predictable and safe. Looking forward, suppliers and drug makers could accelerate new testing methods, faster chemical screening, and tighter traceability. Those improvements wouldn’t just cut costs—they’d give patients and doctors a little more confidence every time a pill slides out of a packet.
People who work in pharmaceuticals want to know what goes into the products they use. ATBC, or acetyl tributyl citrate, gets used as a plasticizer in oral solid dosage forms, along with coatings, capsules, and patches. Its reputation comes from keeping tablets stable without leaching toxins. The big question is always about quality — does the material meet the toughest standards, and how do experts prove that?
You might see terms like BP, EP, and USP on product listings. These mean British Pharmacopoeia, European Pharmacopoeia, and United States Pharmacopeia. Such certifications never guarantee some magical fix, but they do outline what each batch of ATBC must contain. Reputable suppliers test their ATBC with careful chemical analyses: high-performance liquid chromatography, gas chromatography, and other strong methods.
The specifications for these pharma certificates mean the product falls within strict purity ranges. Water content, heavy metals, acidity, and transparency all matter. For ATBC to count as BP/EP/USP grade, it generally runs above 99% purity, with only minuscule traces of water (under 0.25%), and undetectable levels of heavy metals such as lead, arsenic, or mercury. Standard industry results for loss on drying hover around 0.2%, and transparency for color remains nearly crystal-clear.
It isn’t about blind trust in a certificate. Every real-world formulation you encounter — pain relievers, vitamin tablets, allergy medicine — demands an excipient that plays well with fragile ingredients. Any contamination or off-spec material can wind up in the end product, so experts keep a sharp eye. A few years back, I spoke with a QA manager who said small deviations in citrate quality led to batches being scrapped — an expensive setback, especially when operating margins already felt thin. That’s the concrete cost of cutting corners.
For end users and patients, a pharmaceutical grade ensures a safety net against adulteration. Chemicals with food, industrial, or cosmetic grade standards just can’t measure up. Some manufacturers have learned the hard way; regulatory recalls and tainted products don’t just bring lost money, but broken trust. Adhering to BP, EP, or USP signals to buyers that the product holds up to safety checks in quality labs and meets the world’s leading pharmacopeial standards.
Suppliers act carefully — most reputable sources publish comprehensive CoAs (certificates of analysis) that show purity, heavy metal assays, density, refractive index, and an array of impurity assessments. Batch-to-batch consistency is key. In the past, pharma companies sometimes accepted minor defects in excipients, but regulatory pressures grow more intense every year. Many leaders now require full tranparency — from starting material to the sealed bottle.
Other solutions lie in routine supplier audits, independent lab tests, and ongoing dialogue. Buyers ask for traceability — from where the raw material is sourced to what the shipping conditions look like. In my experience, even a single unexplained deviation in test results can spark immediate supplier reviews, which sometimes mean a complete halt in procurement until answers emerge.
ATBC BP/EP/USP grade plays a crucial part in the medication supply chain, far beyond the technical details. Every specification — purity over 99%, ultra-low contaminants, and transparent sourcing — connects to patient safety. That’s where much of a pharmaceutical company’s attention goes: not just to meet a regulatory burden, but to keep their reputation, avoid costly recalls, and protect those who rely on safe, stable medicine.
ATBC, or Acetyl Tributyl Citrate, pops up regularly as a plasticizer in pharmaceutical production. It keeps things like capsules and tablets from crumbling apart and helps with coating processes. Seeing ATBC with the BP, EP, and USP labels signals that it follows the British, European, and US Pharmacopeia standards — no small feat. Those standards demand transparency about everything that goes into the stuff, how pure it comes, and how it acts inside a product meant for real people.
Walking through a manufacturing plant, you notice how many times the word ‘grade’ shows up on ingredient containers. Pharmaceutical grade and food grade are not just marketing tags. Pharmaceutical grade ATBC keeps a tighter leash on things like heavy metals, residual solvents, and impurities. Capsules packed in ATBC plasticizer pass stability testing because regulators trust those standards for quality and consistency.
There’s a reason for all this: even small levels of contamination turn dangerous fast if people take the medicine every day. Around twenty years ago, regulators tightened limits around plasticizers like phthalates due to toxicity concerns. ATBC gained popularity as a safer alternative. According to research from the European Food Safety Authority and FDA updates, ATBC doesn’t build up inside the body, works well in various formulations, and hasn't shown significant toxicity in typical doses. Pharmacopoeial standards set purity limits low — way under the thresholds for organs or sensitive groups.
Experience shows that pharmaceutical ATBC appears in coated tablets, soft gel capsules, and controlled-release technology. Pharmaceutical companies wouldn’t risk recalls or lawsuits unless science and regulations back them up. A review in the International Journal of Toxicology points out that studies involving both animals and human data found ATBC maintains low toxicity and quick clearance.
But there’s no room for shortcuts. Companies dig deep, testing every batch for unwanted byproducts. GMP inspections from agencies stop operations if the product wanders off that tight range. Doctors and pharmacists also look for information in literature and adverse event databases. So far, no clusters of unexpected side effects tied directly to pure pharmaceutical ATBC have been reported.
Still, manufacturers face pressure to prove their ingredient sourcing. Unlabeled or industrial ATBC sneaking into medicine raises all kinds of red flags. Pharmacopeial monographs update regularly to watch for new risks. Labs develop sharper methods to sniff out trace contaminants and sharing public databases allows more scrutiny from independent scientists.
What makes a big difference behind the scenes? Documentation and traceability. Each container of ATBC in pharma grade carries batch numbers, certificates of analysis, and signed-off testing routines. If any doubt arises, recalls track directly to the offending lot. In my work with pharmaceutical audits, strong supply chain controls separate companies that keep patients safe from those courting trouble.
Pharma-grade ATBC, supported by modern production controls and hard-won regulatory experience, stands as a safe choice. Patients and families trust that those medicines don’t bring along invisible health risks. The job isn’t done by standards alone — but by holding every new batch, every supplier, and every process accountable to something higher than the minimum.
Atbc BP EP USP Pharma Grade ends up on the bench in labs and factories that deal with some of the strictest rules around. This plasticizer often goes into medicine coatings and sensitive formulations, so shelf life turns into a real question. ATBC, or acetyl tributyl citrate, usually holds a shelf life of about two years from the date of manufacture if stored properly. Most producers will stamp a best-before date right on the drum or container. Ignore it, and degradation starts to creep in, changes show up in texture, color, and sometimes odor, turning a trusted ingredient into a possible liability.
Leaving a drum of Atbc exposed to air, heat, or moisture invites trouble. Atbc holds up best between 15°C and 30°C, kept tightly sealed in its original packaging. Humidity sneaks through open or poorly-sealed lids, and temperature swings speed up chemical changes. From personal experience in managing raw material stockrooms for pharmaceutical manufacturing, I’ve seen temperature data-loggers catch heat spikes high enough to ruin entire lots. Left unchecked, ATBC’s color can darken and acid value can rise, both signs the product is no longer up to spec.
ATBC goes into products that touch a patient’s lips or body, which puts extra weight on quality. Outdated or poorly stored ATBC risks throwing off physical or chemical properties in the finished product. Pharmaceuticals count on predictable ingredient behavior—one wrong batch can cost more than just money. A change in the plasticizer’s volatility could end up affecting how a tablet releases medication, which can’t be risked. Regulatory authorities make spot checks and auditors have little tolerance for records showing expired or improperly stored excipients.
Safe storage isn’t complicated, but it needs routine. Store in an area with rock-steady temperatures and low humidity. Keep ATBC in tightly closed containers, away from direct sunlight and sources of heat. Pallets should sit off the ground; direct contact with cold warehouse floors or damp patches can increase risk. Each opening and closing of a container increases exposure to air, so breaking bulk into smaller containers in a cleanroom setting can make a difference. Records of temperature logs, regular stock rotation using FIFO (first in, first out), and routine checks for signs of contamination or degradation support a culture of quality.
If a batch runs past expiry or shows signs of breakdown, don’t risk it. Incineration or disposal as hazardous waste, following local laws, remains the safest approach. Regular audits and forecasting can limit wastage, so stock numbers don’t pile up unused material.
Handling ATBC with care supports both product integrity and patient trust. Manufacturers owe it to themselves and their customers to pay attention to storage, treat every container of ATBC as if it could make or break the next batch. Quality assurance teams should always have eyes on expiry dates, environmental controls, and keep suppliers accountable for transporting stock under proper conditions. Better habits today save trouble down the line.
ATBC, or Acetyl Tributyl Citrate, plays a substantial role in pharmaceutical manufacturing. Produced as a plasticizer, ATBC shows up in tablet coatings, capsules, and even packaging films. I’ve seen its value up close; quality excipients like this keep medicines consistent and safe for patients. But the real question facing both manufacturers and consumers: Does pharma-grade ATBC meet tough international benchmarks like BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia)?
These standards—BP, EP, USP—each set strict rules for identity, purity, strength, and safety. For ATBC, the focus narrows in on impurities, moisture, phthalates, and even odor. Contaminants above the threshold can end up causing harm, and packaging plays a part in keeping products stable. I’ve spoken with pharmaceutical quality control teams who rely on these standards not as red tape, but as guardrails protecting patients.
Plenty of stakeholders assume “pharma grade” guarantees total compliance. Not always true. A certificate can claim ATBC matches BP, EP, USP, but paperwork isn’t enough. Independent analysis from a third-party lab remains critical. I’ve seen labs in Europe and the US reject entire shipments based on missed parameters—a missed impurity test, a pH slightly out of range, or even a hint of off odor that spells trouble in downstream applications. Even reputable suppliers face scrutiny.
With raw materials flowing in from multiple regions, pharmaceutical companies need more than a single certificate. Cross-contamination with non-pharma grades can leave holes in compliance. Traceability makes a difference. Knowing every step of the supply chain gives companies confidence to make claims about their ingredients’ compliance with global pharmacopeias. I’ve sat in meetings where auditors demanded batch records, test results, and supplier audits before letting an excipient near a medicine line.
The impact of a shortcut or overlooked test lands on the end user—the patient. Pharmaceutical brands rely on their reputation for safety. Markets like the EU and US enforce penalties and even product recalls over excipient issues. In 2022, the US FDA’s annual report pointed to several product holds due to problems with inactive ingredients. Not all made headlines, but anyone who’s worked in pharma knows about the tension that follows a failed audit or surprise test finding.
Regular independent testing holds every link in the supply chain accountable. Pharmaceutical companies working with suppliers on improvement projects—especially for documentation and analytical controls—can close loopholes. Sharing data, pushing for full digital traceability, and promoting transparency help lift every supplier to a higher standard. I’ve worked alongside teams who trusted only those partners willing to open up their labs and records, not just send certificates.
ATBC labeled as BP, EP, or USP pharma grade should signal confidence to buyers. But diligence makes a bigger difference than any label. For any pharmaceutical excipient, trust builds through transparency, thorough testing, and an unbroken chain of custody. In my experience, companies that stick to these habits never need to scramble after surprise recalls or regulatory letters, and that means safer medicines for everyone.
| Pharmacology | |
| ATC code | ATC code not assigned |
Chengguan District, Lanzhou, Gansu, China
